FDA puts Pharmasset's hepatitis C drug on fast track

10/24/2007 | Forbes

Pharmasset's chronic hepatitis C drug candidate R7128 has obtained fast-track status from the FDA. The company is currently testing the effectiveness of the drug in combination with Pegasys and Copegus in chronic hepatitis C patients who have stopped responding to other treatments.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA